Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.

ABSTRACT:

Objectives

To evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19.

Methods

We conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patients with mild-to-moderate COVID-19 pneumonia. Patients were randomly assigned to receive favipiravir alone (n = 24) or nafamostat with favipiravir (n = 21). The outcomes included changes in the World Health Organization clinical progression scale score, time to improvement in body temperature, and improvement in oxygen saturation (SpO₂).

Results

There was no significant difference in the changes in the clinical progression scale between nafamostat with favipiravir and favipiravir alone groups (median, -0.444 vs -0.

SUBMITTER: Ikeda M 

PROVIDER: S-EPMC9810545 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature